‘King Kong’ drug Mounjaro now in short supply into 2024

Recently launched diabetes med with weight loss hype another victim of ‘larger than expected demand’ Mounjaro, the hotly anticipated competitor to social media-hyped diabetes and de facto weight loss drug Ozempic, has itself become the victim of unexpected demand, seemingly primarily from the off-label weight-loss market. Quietly launched barely two months ago in comparatively inconvenient